1Department of Radiation Oncology, The Catholic University of Korea, Seoul, Korea.
2Department of Diagnostic Radiology, The Catholic University of Korea, Seoul, Korea.
3Department of Clinical Pathology, The Catholic University of Korea, Seoul, Korea.
4Department of Head & Neck Surgery, The Catholic University of Korea, Seoul, Korea.
5Department of Medical Oncology, The Catholic University of Korea, Seoul, Korea.
Copyright © 2008 Korean Cancer Association
The preliminary results of this study were presented at the 2005 annual meeting of the European Society of Therapeutic Radiology and Oncology.
*five-year overall survival rate, †five-year progression-free survival rate, ‡radiotherapy, §concurrent chemoradiotherapy, ∥Combined chemoradiotherapy includes 3 treatment arms: induction chemotherapy followed by radiotherapy; concurrent chemoradiotherapy; and induction chemotherapy followed by concurrent chemoradiotherapy.
Patient characteristics
Treatment outcome according to treatment modality
*five-year overall survival rate, †five-year progression-free survival rate, ‡radiotherapy, §concurrent chemoradiotherapy, ∥Combined chemoradiotherapy includes 3 treatment arms: induction chemotherapy followed by radiotherapy; concurrent chemoradiotherapy; and induction chemotherapy followed by concurrent chemoradiotherapy.
Tumor response after chemoradiation and RT alone
*combined chemo-RT includes 3 treatment arms: induction chemotherapy followed by radiotherapy; concurrent chemoradiotherapy; and induction chemotherapy followed by concurrent chemoradiotherapy, †radiotherapy, ‡complete response, §partial response, ∥minimal response.
Pattern of failure at last assessment
*combined chemo-RT includes 3 treatment arms: induction chemotherapy followed by radiotherapy; concurrent chemoradiotherapy; and induction chemotherapy followed by concurrent chemoradiotherapy, †radiotherapy.
Acute toxicities (%) by RTOG/WHO criteria
*combined chemo-RT includes 3 treatment arms: induction chemotherapy followed by radiotherapy; concurrent chemoradiotherapy; and induction chemotherapy followed by concurrent chemoradiotherapy, †radiotherapy.
Prognostic factors associated with overall survival and progression-free survival on univariate analysis
*five-year overall survival rate, †five-year progression-free survival rate, ‡complete response, §partial response, ∥radiotherapy, ¶concurrent chemoradiotherapy.
*five-year overall survival rate, †five-year progression-free survival rate, ‡radiotherapy, §concurrent chemoradiotherapy, ∥Combined chemoradiotherapy includes 3 treatment arms: induction chemotherapy followed by radiotherapy; concurrent chemoradiotherapy; and induction chemotherapy followed by concurrent chemoradiotherapy.
*combined chemo-RT includes 3 treatment arms: induction chemotherapy followed by radiotherapy; concurrent chemoradiotherapy; and induction chemotherapy followed by concurrent chemoradiotherapy, †radiotherapy, ‡complete response, §partial response, ∥minimal response.
*combined chemo-RT includes 3 treatment arms: induction chemotherapy followed by radiotherapy; concurrent chemoradiotherapy; and induction chemotherapy followed by concurrent chemoradiotherapy, †radiotherapy.
*combined chemo-RT includes 3 treatment arms: induction chemotherapy followed by radiotherapy; concurrent chemoradiotherapy; and induction chemotherapy followed by concurrent chemoradiotherapy, †radiotherapy.
*five-year overall survival rate, †five-year progression-free survival rate, ‡complete response, §partial response, ∥radiotherapy, ¶concurrent chemoradiotherapy.